Sequential Ruthenium Catalysis for Olefin Isomerization and Oxidation: Application to the Synthesis of Unusual Amino Acids
- Creators
-
Liniger, Marc
- Liu, Yiyang
-
Stoltz, Brian M.
Abstract
How can you use a ruthenium isomerization catalyst twice? A ruthenium-catalyzed sequence for the formal two-carbon scission of allyl groups to carboxylic acids has been developed. The reaction includes an initial isomerization step using commercially available ruthenium catalysts followed by in situ transformation of the complex to a metal-oxo species, which is capable of catalyzing subsequent oxidation reactions. The method enables enantioselective syntheses of challenging α-tri- and tetrasubstituted α-amino acids including an expedient total synthesis of the antiepileptic drug levetiracetam.
Additional Information
© 2017 American Chemical Society. Received: August 10, 2017; Published: September 16, 2017. Dedicated to Professor Albert Padwa on the occasion of his 80th birthday. The authors wish to thank NIH-NIGMS (R01GM080269), Amgen, the Gordon and Betty Moore Foundation, and Caltech for financial support. M.L. thanks the Swiss National Science Foundation (SNSF) for a postdoctoral fellowship (P2EZP2_148751). Dr. Scott Virgil and the Caltech Center for Catalysis and Chemical Synthesis are acknowledged for the generous donation of catalyst 2 and Materia Inc. for the donation of catalyst 1a. The authors thank Dr. Michael Takase and Larry Henling for X-ray structural determinations. The Hsieh-Wilson group is acknowledged for nanopure water and the Dougherty group for using their freeze-drying equipment. Lukas Hilpert, Kyle Virgil, and Katerina Korch are thanked for experimental assistance. Dr. Beau P. Pritchett is gratefully acknowledged for recording analytical data and for proofreading the manuscript. The authors declare no competing financial interest.Attached Files
Accepted Version - nihms906975.pdf
Supplemental Material - ja7b08496_si_001.pdf
Supplemental Material - ja7b08496_si_002.cif
Supplemental Material - ja7b08496_si_003.cif
Supplemental Material - ja7b08496_si_004.cif
Supplemental Material - ja7b08496_si_005.cif
Supplemental Material - ja7b08496_si_006.cif
Supplemental Material - ja7b08496_si_007.cif
Supplemental Material - ja7b08496_si_008.cif
Supplemental Material - ja7b08496_si_009.cif
Supplemental Material - ja7b08496_si_010.cif
Supplemental Material - ja7b08496_si_011.cif
Supplemental Material - ja7b08496_si_012.cif
Supplemental Material - ja7b08496_si_013.cif
Supplemental Material - ja7b08496_si_014.cif
Supplemental Material - ja7b08496_si_015.cif
Files
Name | Size | Download all |
---|---|---|
md5:9e3b447f8aae6baec38de568ce81aa7f
|
1.7 MB | Download |
md5:9dddb369c24e1a2f45b221f61aba9dd0
|
43.3 MB | Preview Download |
md5:a6eb5caaa8719d3c7023f826ace79864
|
947.3 kB | Download |
md5:b672cb0bec1603a3b257d878cc01a8d2
|
1.1 MB | Download |
md5:b552d56d03ce9b99f68dee7bf15fe311
|
654.5 kB | Download |
md5:6fbf0f43f795f1277b3d6d706ed88a47
|
167.3 kB | Download |
md5:d41033ac8f5b4b1e2e93f4ef406514e9
|
2.1 MB | Download |
md5:265b4d0990372b42d517d083fc6abf50
|
342.7 kB | Download |
md5:0fc20edb0f89cb34b7bf79b39fd7c221
|
766.3 kB | Download |
md5:4facf05e8ba5e5eaa83387d1d78595d0
|
1.5 MB | Download |
md5:a08390b1ac61e7d1beaaf071b7368e2d
|
1.8 MB | Download |
md5:77b0b000ef02ad195ed673674f2b7675
|
220.2 kB | Download |
md5:7c6bdfff47e549ed9ec132c50ac3aa38
|
971.4 kB | Preview Download |
md5:9ebf3858108c9b428c9a2967ef6bcefa
|
879.5 kB | Download |
md5:ef7fdc664dc939634f43fa2a52e1cb53
|
1.4 MB | Download |
md5:e8e6269fa2ac381a6594f3b14a15c208
|
437.8 kB | Download |
Additional details
- PMCID
- PMC5628162
- Eprint ID
- 81521
- DOI
- 10.1021/jacs.7b08496
- Resolver ID
- CaltechAUTHORS:20170918-101644915
- NIH
- R01GM080269
- Amgen
- Gordon and Betty Moore Foundation
- Caltech
- Swiss National Science Foundation (SNSF)
- P2EZP2_148751
- Created
-
2017-09-18Created from EPrint's datestamp field
- Updated
-
2022-03-22Created from EPrint's last_modified field